Investors Urged to Join Skye Bioscience Securities Fraud Lawsuit

The Rosen Law Firm is inviting investors who purchased securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024, and October 3, 2025, to participate in a class action lawsuit concerning alleged securities fraud. The deadline to apply as a lead plaintiff is set for January 16, 2026.

Investors who acquired shares during the specified period may be entitled to compensation without incurring out-of-pocket fees through a contingency fee arrangement. The lawsuit claims that Skye made materially false and misleading statements about its business operations and the effectiveness of its lead product, nimacimab.

Details of the Allegations

According to the lawsuit, the defendants overstated the clinical, regulatory, and commercial prospects of nimacimab. Specifically, they allegedly misrepresented the drug’s effectiveness, leading investors to believe it was more promising than it actually was. The lawsuit contends that these misleading statements caused significant financial harm to investors once the true nature of the drug and its prospects became clear.

Interested investors can join the class action by visiting the official submission page or by contacting Phillip Kim, Esq. at 866-767-3653 or via email at [email protected]. It is important to note that a class has not yet been certified, therefore, individuals are not represented unless they retain legal counsel.

Why Choose Rosen Law Firm?

The Rosen Law Firm emphasizes its expertise in securities class actions, having achieved a record for the largest securities class action settlement against a Chinese company. The firm was ranked first by ISS Securities Class Action Services in 2017 for the number of settlements achieved and has consistently ranked among the top firms in this field since 2013. In 2019, the firm secured over $438 million for its clients.

Investors are advised to carefully select qualified counsel with a proven track record in similar cases. The Rosen Law Firm encourages potential plaintiffs to be cautious of firms that primarily act as intermediaries rather than actively litigating cases.

For more information on the class action and updates, investors can follow the Rosen Law Firm on LinkedIn, Twitter, and Facebook.

Attorney advertising is applicable, and prior results do not guarantee a similar outcome.